Healthcare Capital Corp Class A HCCC 深 沪
等待开盘 05-20 09:30:00 美东时间
12.74
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 12.74
- 总市值 43.79万
- 52周最高 14.78
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 8.20
- 委 比 0.00%
- 总股本 3.44万
- 历史最高 14.78
- 量 比 0
- 振 幅 0.00%
- 历史最低 8.20
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Artiva Biotherapeutics Announces Pricing of $300 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Artiva Biotherapeutics announced an underwritten offering of 23,871,526 shares of common stock at $11.52 per share and pre-funded warrants for 2,170,138 shares, raising approximately $300 million. The offering includes participation from major investors and is expected to close on May 11, 2026. Artiva, a biotech company focused on developing cell therapies for autoimmune diseases, plans to use the proceeds to advance its AlloNK program, targeting...
05-08 10:52
Korro Reports First Quarter 2026 Financial Results and Provides Corporate Update
Korro Bio reported Q1 2026 progress, highlighting KRRO-121's potential as a first-in-class treatment for hyperammonemia in urea cycle disorders and hepatic encephalopathy, with regulatory filing expected in H2 2026. The company advanced its GalNAc-conjugated oligonucleotide for alpha-1 antitrypsin deficiency, achieving >90% in vivo RNA editing. Korro executed an $85M private placement to extend cash runway into H2 2028 and support multiple RNA ed...
05-07 11:00
Century Therapeutics Reports Full Year 2025 Financial Results and Business Updates
Century Therapeutics reported financial results for 2025 and highlighted progress in developing cell therapies for type 1 diabetes and cancer. The company expects to submit an IND for CNTY-813, a potential functional cure for type 1 diabetes, in Q4 2026, with initial clinical data anticipated in H2 2027. CNTY-308, targeting B-cell-mediated diseases, is on track to enter the clinic in 2026. Century strengthened its balance sheet with a $135 millio...
03-12 12:00
Korro Bio Secures ~$85M PIPE Financing Via Subscription Agreement
Financing led by new investor Venrock Healthcare Capital Partners, with participation from new and existing investors Proceeds support the achievement of value inflection points for multiple RNA editing programs
03-09 19:36
Relmada Therapeutics Announces Oversubscribed $160.0 Million Private Placement Financing
Relmada Therapeutics, a biotechnology company, has secured approximately $160 million through a PIPE financing, with participation from leading investors. The transaction includes 29.47 million common shares and pre-funded warrants for 4.21 million shares. Proceeds will support working capital, general corporate purposes, and advancing R&D efforts. The financing is expected to close on March 11, 2026.
03-09 11:05
Crescent Biopharma Raises $185 Million in Private Placement
Crescent Biopharma Inc. has announced a private placement of approximately $185 million in securities to institutional and accredited investors. The offering, which is expected to close around Decembe...
2025-12-04 19:37
German biotech firm Tubulis raises $358 million to develop targeted cancer treatments
Tubulis, with latest funding, has raised 495 million euros Funds aim to expand trials of a lead cancer treatment product Market for targeted treatments may reach $31 billion by 2030 By Bhanvi Satija L...
2025-10-15 17:00
快讯 | Newmark任命Justin Shepherd为美国医疗保健资本市场团队的联席负责人
Newmark Appoints Justin Shepherd as Co-Head of U.S. Healthcare Capital Markets ...
2025-03-13 01:04
医疗保健资本公司宣布休会股东特别会议
NEW YORK, NY, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Healthcare Capital Corp. (NASD...
2022-02-16 04:26
SPAC动态 | 吉利旗下极星拟通过SPAC上市，估值或超100亿美元
美国最大的社区社交平台Nextdoor计划借道SPAC上市，其PIPE投资者包括Ark Invest；加密货币运营商Circle宣布将与SPAC公司CND合并上市 >>
2021-07-09 16:49
